AVOIDANCE AND MANAGEMENT OF ADVERSE REACTIONS TO ANTITUBERCULOSIS DRUGS

被引:29
作者
PATEL, AM
MCKEON, J
机构
[1] Queensland Health Chest Clinic, Brisbane, Queensland, 4002, PO Box 232, North Quay
关键词
D O I
10.2165/00002018-199512010-00001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Potent antibiotics are required to cure tuberculosis and reduce the burden of illness in the community. Minor adverse-effects are commonly encountered and can be managed by reassurance and explanation. Significant hypersensitivity reactions require cessation of all antituberculosis drugs. Adverse effects should be treated appropriately. An effective antituberculosis regimen should be re-established as soon as possible. Desensitisation may be necessary if suitable alternative drugs cannot be used. In the event of drug-induced hepatitis, all hepatotoxic drugs should be ceased until symptoms resolve and liver function tests return to normal. Other significant direct toxic effects should be promptly detected and appropriately treated. A thorough knowledge of potential adverse reactions and pharmacokinetics is essential for any physician using antituberculosis drugs.
引用
收藏
页码:1 / 25
页数:25
相关论文
共 160 条
[31]  
Kohno S., Koga H., Kaku M., Et al., Prospective comparative study of ofloxacin or ethambutol for treatment of pulmonary tuberculosis, Chest, 102, (1992)
[32]  
Kennedy N., Fox R., Kisyombe G.M., Et al., Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis, Am Rev Respir Dis, 148, (1993)
[33]  
Flor S., Pharmacokinetics of ofloxacin, Am J Med, 87, 6 C, pp. 24S-30S, (1989)
[34]  
Gonzalez-Montaner L.J., Natal S., Yongchaiyud P., Et al., Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin, Tuber Lung Dis, 75, (1994)
[35]  
Benson C.A., Treatment of disseminated disease due to Mycobacterium avium complex in patients with AIDS, Clin Infec Dis, 18, 3, (1994)
[36]  
Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months, Tubercle, 62, pp. 95-102, (1981)
[37]  
Citron K.M., Somner A.R., Angel J.H., Short duration chemotherapy in pulmonary tuberculosis. The occurrence of hepatitis in six month regimens containing pyrazinamide as well as rifampicin, Am Rev Respir Dis, 121, (1980)
[38]  
Study of chemotherapy regimens of five and seven months duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India, Tubercle, 64, pp. 73-91, (1983)
[39]  
A service programme with a six month intensive chemotherapy regimen in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong, Tubercle, 64, (1983)
[40]  
Controlled trial of 2, 4 and 6 months or pyrazinamide in 6-month three-times-weekly regimens for smear positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide: results at 30 months, Am Rev Respir Dis, 143, (1991)